<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02913365</url>
  </required_header>
  <id_info>
    <org_study_id>12-099</org_study_id>
    <nct_id>NCT02913365</nct_id>
  </id_info>
  <brief_title>Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis</brief_title>
  <official_title>Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis in a North-American Tertiary Center at the Beginning of the 21st Century</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study consist of a retrospective analysis of the etiologies, investigations and outcomes
      of patients presenting between 2005 to 2010 with hemoptysis in a North-American Tertiary
      center.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RATIONALE:

      Hemoptysis, mild or massive, is worrisome for both patients and physicians. The management is
      different depending on the causes, which are not well defined for the North American
      population. Despite the fact that this symptom is commonly reported in clinic, there are only
      a few studies published on this subject in the North-American population. Tuberculosis was a
      frequent cause of hemoptysis described in populations overseas, which seems less prevalent in
      the investigators center.

      Also, there are no known official guidelines regarding the investigation and management of
      hemoptysis. The investigators hypothesized that the use of modern technology in a North
      American population may result in different findings and provide a more accurate diagnostic
      approach.

      Therefore, the study compares the different etiologies of hemoptysis and investigation
      modalities used in patients presenting in a North-American tertiary center.

      METHOD:

      The investigators did a retrospective analysis of medical chart from patients with hemoptysis
      who visited the investigators center between 2005 and 2010. Each visit has been reviewed
      individually to describe the characteristics of patients, etiologies of hemoptysis and
      investigation modalities used. All-cause mortality at 2 years was also recorded.

      Descriptive statistical analyses will conducted on the data available.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Etiologies of hemoptysis</measure>
    <time_frame>5 years</time_frame>
    <description>Defining the prevalence of pulmonary diseases by measuring the percentage of patients presenting with hemoptysis caused by lung cancer, bronchiectasis, pulmonary embolism, arteriovenous fistula, pneumonia, bronchitis, tuberculosis, mycosis, heart failure, pseudohemoptysis, cryptogenic and other causes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of chest X-ray, chest CT-scan and CT-angiography, bronchoscopy, ventilation-perfusion with single-photon emission computed tomography and pulmonary angiography.</measure>
    <time_frame>5 years</time_frame>
    <description>Determining the sensitivity in obtaining the etiology of the hemoptysis episode of each diagnostic modality that follows : chest X-ray, chest CT-scan and CT-angiography, bronchoscopy, ventilation-perfusion with single-photon emission computed tomography and pulmonary angiography in the diagnosis of different etiologies of hemoptysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality at 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>All-cause mortality at 2 years after the diagnosis of hemoptysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smoking status</measure>
    <time_frame>Day 1</time_frame>
    <description>Determining the percentage of patients who : never smoked, is an active smoker, former smoker or unknown status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age</measure>
    <time_frame>Day 1</time_frame>
    <description>Determining the average age of the enrolled patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gender</measure>
    <time_frame>Day 1</time_frame>
    <description>Determining the percentage of each gender of the enrolled patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Normalized Ratio</measure>
    <time_frame>Day 1</time_frame>
    <description>Determining the median of the international normalized ratio (INR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Thromboplastin Time</measure>
    <time_frame>Day 1</time_frame>
    <description>Determining the median of the partial thromboplastin time (PTT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>Day 1</time_frame>
    <description>Determining the average of the platelet count measured per microliter of blood.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hemoptysis</condition>
  <condition>Haemoptysis</condition>
  <condition>Lung Disease</condition>
  <condition>Pneumonia</condition>
  <condition>Tuberculosis</condition>
  <condition>Bronchiectasis</condition>
  <condition>Respiratory Tract Infections</condition>
  <condition>Respiratory Tract Diseases</condition>
  <condition>Bronchitis</condition>
  <condition>Mycobacterium Infections</condition>
  <condition>Bronchial Disease</condition>
  <condition>Pulmonary Hemorrhage</condition>
  <condition>Signs and Symptoms</condition>
  <condition>Signs and Symptoms, Respiratory</condition>
  <condition>Pathologic Processes</condition>
  <condition>Mycosis</condition>
  <condition>Hemorrhage</condition>
  <condition>Lung Cancer</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Arteriovenous Fistula</condition>
  <arm_group>
    <arm_group_label>Patients presenting with hemoptysis</arm_group_label>
    <description>Patients over 18 years of age presenting with hemoptysis at the Centre Hospitalier Universitaire de Sherbrooke (CHUS) between the periods of 2005 to 2010.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient presenting with hemoptysis at the Centre Hospitalier Universitaire de
        Sherbrooke on an outpatient basis, emergency department or hospitalized at hopital
        Fleurimont or Hotel-Dieu of Sherbrooke.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Any patient over the age of 18 presenting with:

          -  A diagnosis of hemoptysis on an outpatient basis.

          -  A diagnosis of hemoptysis during consultation in the emergency department.

          -  A diagnosis of hemoptysis on the admission sheet.

          -  A diagnosis of hemoptysis when hospitalized.

          -  A complication of hemoptysis

          -  Hemoptysis on the report of the bronchoscopy, chest computed tomography, pulmonary
             angiography, ventilation-perfusion single-photon emission computed tomography or blood
             transfusion.

        Exclusion Criteria:

          -  Patients under 18 years of age.

          -  Patient who refused investigation for hemoptysis.

          -  Incomplete medical chart
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Grodin-Beaudoin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Grondin-Beaudoin, MD</last_name>
    <phone>18193461110</phone>
    <email>brian.grondin.beaudoin@usherbrooke.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthieu Poirier, MD</last_name>
    <phone>18193461110</phone>
    <email>matthieu.benoit.jose.poirier@usherbrooke.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Grondin-Beaudoin, MD</last_name>
      <phone>18193461110</phone>
      <email>brian.grondin.beaudoin@usherbrooke.ca</email>
    </contact>
    <contact_backup>
      <last_name>Matthieu Poirier, MD</last_name>
      <phone>18193461110</phone>
      <email>matthieu.benoit.jose.poirier@usherbrooke.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Amelie Blanchard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest. 1997 Aug;112(2):440-4.</citation>
    <PMID>9266882</PMID>
  </reference>
  <reference>
    <citation>Jeudy J, Khan AR, Mohammed TL, Amorosa JK, Brown K, Dyer DS, Gurney JW, MacMahon H, Saleh AG, Vydareny KH; Expert Panel on Thoracic Imaging. ACR Appropriateness Criteria hemoptysis. J Thorac Imaging. 2010 Aug;25(3):W67-9. doi: 10.1097/RTI.0b013e3181e35b0c.</citation>
    <PMID>20711032</PMID>
  </reference>
  <reference>
    <citation>Alaoui AY, Bartal M, el Boutahiri A, Bouayad Z, Bahlaoui A, el Meziane A, Naciri A. [Clinical characteristics and etiology in hemoptysis in a pneumology service. 291 cases]. Rev Mal Respir. 1992;9(3):295-300. French.</citation>
    <PMID>1615202</PMID>
  </reference>
  <reference>
    <citation>Reechaipichitkul W, Latong S. Etiology and treatment outcomes of massive hemoptysis. Southeast Asian J Trop Med Public Health. 2005 Mar;36(2):474-80.</citation>
    <PMID>15916059</PMID>
  </reference>
  <reference>
    <citation>Sanai Raggad S, Abid H, Ghedira H, Tritar F, Hamzaoui A. [Current etiologies of hemoptysis in the elderly: comparative study of 360 cases]. Tunis Med. 2010 Nov;88(11):809-13. French.</citation>
    <PMID>21049410</PMID>
  </reference>
  <reference>
    <citation>Unsal E, Köksal D, Cimen F, Taci Hoca N, Sipit T. Analysis of patients with hemoptysis in a reference hospital for chest diseases. Tuberk Toraks. 2006;54(1):34-42.</citation>
    <PMID>16615016</PMID>
  </reference>
  <reference>
    <citation>Prasad R, Garg R, Singhal S, Srivastava P. Lessons from patients with hemoptysis attending a chest clinic in India. Ann Thorac Med. 2009 Jan;4(1):10-2. doi: 10.4103/1817-1737.43062.</citation>
    <PMID>19561915</PMID>
  </reference>
  <reference>
    <citation>Soares Pires F, Teixeira N, Coelho F, Damas C. Hemoptysis--etiology, evaluation and treatment in a university hospital. Rev Port Pneumol. 2011 Jan-Feb;17(1):7-14. English, Portuguese.</citation>
    <PMID>21251478</PMID>
  </reference>
  <reference>
    <citation>Pedrol E, Fernández-Solá J, Ferrer M, Barceló J, Bosch X, Sandé L, Camp J, Borrás A, Urbano-Márquez A. [Hemoptysis: a prospective study of 108 cases in an emergency service]. Rev Clin Esp. 1991 May;188(9):450-4. Spanish.</citation>
    <PMID>1896592</PMID>
  </reference>
  <reference>
    <citation>Tsoumakidou M, Chrysofakis G, Tsiligianni I, Maltezakis G, Siafakas NM, Tzanakis N. A prospective analysis of 184 hemoptysis cases: diagnostic impact of chest X-ray, computed tomography, bronchoscopy. Respiration. 2006;73(6):808-14. Epub 2006 Jan 27.</citation>
    <PMID>16446530</PMID>
  </reference>
  <reference>
    <citation>Wong CM, Lim KH, Liam CK. The causes of haemoptysis in malaysian patients aged over 60 and the diagnostic yield of different investigations. Respirology. 2003 Mar;8(1):65-8.</citation>
    <PMID>12856744</PMID>
  </reference>
  <reference>
    <citation>Haro Estarriol M, Vizcaya Sánchez M, Jiménez López J, Tornero Molina A. [Etiology of hemoptysis: Prospective analysis of 752 cases]. Rev Clin Esp. 2001 Dec;201(12):696-700. Spanish.</citation>
    <PMID>11835879</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Brian Grondin-Beaudoin</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Haemoptysis</keyword>
  <keyword>Hemoptysis</keyword>
  <keyword>Airway bleeding</keyword>
  <keyword>Pulmonary hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Pathologic Processes</mesh_term>
    <mesh_term>Hemoptysis</mesh_term>
    <mesh_term>Bronchial Diseases</mesh_term>
    <mesh_term>Signs and Symptoms, Respiratory</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

